

35. (Twice Amended) A composition comprising the isolated peptide of any of Claims 2-4, 6, 14 or 22 and a pharmaceutically acceptable carrier.

Please add the following claim:

29-45. A pharmaceutical composition comprising the isolated peptide of SEQ ID NO: 24 and a pharmaceutically acceptable carrier.

REMARKS

Claims 2-33 and 35 are pending in the present application. Claims 2-32 are directed to isolated IL-16 antagonist peptides. Claim 33 is directed to an isolated nucleic acid molecule coding for an IL-16 antagonist peptide. Claim 35 is directed a pharmaceutical composition comprising an IL-16 antagonist peptide and a pharmaceutically acceptable carrier.

In the Final Action dated June 6, 2002, claims 1-33 and 35 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking enabling support. Claim 35 is also separately rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking enabling support. Claim 1-33 and 35 are further rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite.

Applicants submitted a § 1.116 Amendment in response to the Final Action. The Examiner in turn issued an Advisory Action, in which the Examiner states that Applicants' response has overcome the rejection of claims 2-33 under 35 U.S.C. § 112, first paragraph (enablement) and the rejection of claims 2-33 and 35 under 35 U.S.C. § 112, second paragraph.

Claim 35 remains rejected in the Advisory Action under 35 U.S.C. § 112, first paragraph, as allegedly not enabled. The Examiner admits that the specification is enabling for a composition comprising an isolated IL-16 antagonist peptide consisting of the amino acid sequence of SEQ ID NO: 2, 5, 6, 17, and 24 and a pharmaceutically acceptable carrier. The Examiner also admits that the specification is enabling for a pharmaceutical composition